BASKING RIDGE, N.J., Feb. 13 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, will be presenting at the BIO CEO & INVESTOR CONFERENCE on Wednesday February 14, 2007 at 3:45 PM (EST) at the WALDORF- ASTORIA HOTEL in New York City. VioQuest’s President and CEO, Daniel Greenleaf, will provide an overview of the Company and an update on its clinical development programs, including its two targeted cancer agents, VQD-001, currently in Phase I/IIa clinical trials for solid tumors, and VQD-002 in clinical trials for leukemia and solid tumors. Additionally, Mr. Greenleaf will discuss the upcoming NDA filing for leishmaniasis for VQD-001.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )
About VioQuest Pharmaceuticals
VioQuest Pharmaceuticals, Inc. www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which appears to inhibit phosphorylation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and VQD-001, an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for VQD-001 for the treatment of leishmaniasis. VioQuest’s subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. VioQuest is seeking strategic alternatives for Chiral Quest, which may include its sale.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest’s actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest’s planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Further, there us no assurance that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that its planned and ongoing clinical trials will not be initiated or completed as anticipated, that the results of clinical trials will not support VioQuest’s claims, the possibility that VioQuest’s development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest’s product candidates, VioQuest’s reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest’s Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Photo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGOVioQuest Pharmaceuticals, Inc.
CONTACT: Daniel Greenleaf, President and CEO, +1-908-766-4400, ext. 115,dan.greenleaf@vioquestpharm.com; Brian Lenz, CFO, +1-908-766-4400, ext.117, brian.lenz@vioquestpharm.com; Diane Perry, VP, Investor Relations &Corporate Communications, +1-917-834-7526, +1-908-766-4400, ext. 116,diane.perry@vioquestpharm.com
Web site: http://www.vioquestpharm.com/
